Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Palmex is a natural phytotherapeutic agent and nutritional supplement developed by the Centro Nacional de Investigaciones Científicas (CNIC) in Cuba for the treatment of benign prostatic hyperplasia (BPH). It consists of a lipid extract derived from the fruits of the Cuban royal palm (*Roystonea regia*), containing a mixture of free fatty acids such as oleic, palmitic, and lauric acids. Palmex exerts its therapeutic effects through a multi-targeted mechanism, including the inhibition of the enzyme 5α-reductase (which prevents the conversion of testosterone to dihydrotestosterone), antagonism of α1-adrenoreceptors (promoting smooth muscle relaxation in the prostate and bladder neck), and antioxidant activity that reduces oxidative stress in prostate tissue. Clinical trials have demonstrated that Palmex is effective in improving lower urinary tract symptoms (LUTS), increasing maximum urinary flow, and reducing prostate volume, with a safety profile comparable to standard pharmacological treatments like finasteride and tamsulosin.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Palmex.